Medical imaging, which empowers the detection of physiological and pathological processes within living subjects, has a vital role in both preclinical and clinical diagnostics. Contrast agents are ...

The FDA has approved Ambelvist, a macrocyclic gadolinium-based option for contrast-enhanced MRI, now the lowest ...

Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...

The rate of hypersensitivity reactions (HSRs) to gadolinium-based contrast agents (GBCAs) is 0.4 percent, and premedication can reduce the risk for HSRs in patients with a history of acute or delayed ...

Skoltech researchers and their colleagues have synthesized and tested protein-polymer microbubbles for use in medical ultrasound imaging of internal organs. Administered intravenously, the ...

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

The approval is based on global Phase III QUANTI studies evaluating Ambelvist's efficacy and safety in adults and children.

A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...

Gadolinium (Gd)-based contrast agents (GBCAs) are chemicals injected intravenously during magnetic resonance imaging to enhance the diagnostic yield. Repeated use of GBCAs causes their deposition in ...

The FDA has approved Bayer’s Ambelvist (gadoquatrane), the lowest-dose macrocyclic GBCA for adult and pediatric contrast-enhanced CNS and body MRI exams.